Mark Stein, PhD, ABPP

Personal Statement

I am a Profesor of Psychiatry, Adjunct Professor of  Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s and Seattle Children’s at Overlake Hospital in Bellevue. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s and schools. The majority of my clinical work involves  diagnostic evaluations and consultations. Treatment recommendations are made for the parents, referring physician, and schools. I also direct the clinical program for SEA STAR, a summer treatment program for children with ADHD and related disorders that targets social impairment and self-esteem, in collaboration with the UW Autism Center.

Comparative efficacy and personalized ADHD treatment are major themes of my work. I have published over 120 articles, mostly having to do with ADHD diagnosis and treatment in all ages, and specific areas within ADHD such as genetics, thyroid, and sleep . I have  participated in numerous clinical trials of stimulant  and non stimulant medications. Current research studies involve parents with ADHD, children with ADHD and Autism, and a new NIH sponsored study examining the effects of abruptly discontinuing methylphenidate in children with ADHD.

Other areas of interest include sleep problems and overlap with ADHD, pediatric psychology, and research ethics. Finally, I participate in the ITHS Treatment Innovatiopn Center, focusing on removing barriers to multi-site clinical and translational studies.

Education

Medical school: Southern Illinois University - Carbondale
Fellowship: MacLean Center for Clinical Medical Ethics, Chicago

Department Affiliations

Other Affiliations

PEARL Clinic, Director – Seattle Children’s Hospital
Training Clinic

Recent Publications

Evaluating the Feasibility and Acceptability of the Lifestyle Enhancement for ADHD Program.
(2021 Jul 20)
J Pediatr Psychol 46(6): 662-672
Ola C, Gonzalez E, Tran N, Sasser T, Kuhn M, LaCount PA, Stein MA, Mendoza JA, Tandon PS

Telemedicine in management of genitourinary malignancies: Patient and physician perspectives.
(2021 Aug)
Urol Oncol 39(8): 480-486
Margolin EJ, Pina Martina LA, Miles CH, Wenske S, McKiernan JM, DeCastro GJ, Hyams ES, Drake CG, Lim EA, Stein MN, Deutsch I, Anderson CB

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
(2021 Jun)
Lancet Oncol 22(6): 872-882
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV

Predictors of Treatment Engagement and Outcome Among Adolescents With Attention-Deficit/Hyperactivity Disorder: An Integrative Data Analysis.
(2021 Jun 5)
J Am Acad Child Adolesc Psychiatry
Sibley MH, Coxe SJ, Stein MA, Meinzer MC, Valente MJ

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
(2021 Apr 20)
J Clin Oncol 39(12): 1371-1382
Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES

Show complete publication list »
Edit Profile